The Experts below are selected from a list of 5007 Experts worldwide ranked by ideXlab platform
Jocelien D. A. Olivier - One of the best experts on this subject based on the ideXlab platform.
-
The effect of Antenatal Depression and antidepressant treatment on placental tissue: a protein-validated gene expression study.
BMC pregnancy and childbirth, 2019Co-Authors: Åsa Edvinsson, Charlotte Hellgren, Susanne Lager, Romina Fornes, Helena Akerud, Alkistis Skalkidou, Olav Spigset, Elisabet Stener-victorin, Theodora Kunovac Kallak, Jocelien D. A. OlivierAbstract:Antenatal Depression affects 10–20% of pregnant women. Around 2–4% of European pregnant women use antidepressant treatment, most commonly selective serotonin reuptake inhibitors (SSRIs). Poor pregnancy outcomes, such as preterm birth and low birth weight, have been described in women with Antenatal Depression and in pregnant women on SSRI treatment. However, the effects of Antenatal Depression and antidepressant treatment on the placenta are largely unknown. The aim of this work was to compare placental gene and protein expression in healthy women, women with untreated Antenatal Depression and women on antidepressant treatment during pregnancy. Placental samples from 47 controls, 25 depressed and 45 SSRI-treated women were analysed by means of qPCR using custom-designed TaqMan low-density arrays (TLDAs) for 44 genes previously known to be involved in the pathophysiology of Depression, and expressed in the placenta. Moreover, placental protein expression was determined by means of immunohistochemistry in 37 healthy controls, 13 women with untreated Depression and 21 women on antidepressant treatment. Statistical comparisons between groups were performed by one-way ANOVA or the Kruskal–Wallis test. Nominally significant findings were noted for HTR1A and NPY2R, where women with untreated Depression displayed higher gene expression than healthy controls (p
-
The effects of Antenatal Depression and antidepressant treatment on placental gene expression
Frontiers in cellular neuroscience, 2015Co-Authors: Jocelien D. A. Olivier, Helena Akerud, Alkistis Skalkidou, Helena Kaihola, Inger Sundström-poromaaAbstract:The effects of Antenatal Depression and antidepressant treatment during pregnancy on both mother and child are vigorously studied, but the underlying biology for these effects is largely unknown. The placenta plays a crucial role in the growth and development of the fetus. We performed a gene expression study on the fetal side of the placenta to investigate gene expression patterns in mothers with Antenatal Depression and in mothers using antidepressant treatment during pregnancy. Placental samples from mothers with normal pregnancies, from mothers with Antenatal Depression, and from mothers using antidepressants were collected. We performed a pilot microarray study to investigate alterations in the gene expression and selected several genes from the microarray for biological validation with qPCR in a larger sample. In mothers with Antenatal Depression 108 genes were differentially expressed, whereas 109 genes were differentially expressed in those using antidepressants. Validation of the microarray revealed more robust gene expression differences in the seven genes picked for confirmation in antidepressant-treated women than in depressed women. Among the genes that were validated ROCK2 and C12orf39 were differentially expressed in both depressed and antidepressant-treated women, whereas ROCK1, GCC2, KTN1, and DNM1L were only differentially expressed in the antidepressant-treated women. In conclusion, Antenatal Depression and antidepressant exposure during pregnancy are associated with altered gene expression in the placenta. Findings on those genes picked for validation were more robust among antidepressant-treated women than in depressed women, possibly due to the fact that Depression is a multifactorial condition with varying degrees of endocrine disruption. It remains to be established whether the alterations found in the gene expression of the placenta are found in the fetus as well.
M Amalan - One of the best experts on this subject based on the ideXlab platform.
-
Prevalence of Antenatal Depression in South Asia: a systematic review and meta-analysis
European Journal of Public Health, 2020Co-Authors: Rahini Mahendran, Shuby Puthussery, M AmalanAbstract:Abstract Background Antenatal Depression carries significant adverse implications for the health and well-being of women, babies and their families. While prevalence of perinatal mental disorders in low-and lower-middle-income countries tends to be higher compared to high-income countries, rates tend to vary widely among countries in certain regions such as South Asia. This study estimated the pooled prevalence of Antenatal Depression in South Asia and examined variations in individual countries. Methods We conducted a systematic review and meta-analysis. A comprehensive search was conducted on thirteen electronic databases and grey sources for articles published between 1·1·2007 and 31·5·2018 from South Asian countries including Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka. Studies reporting quantitative prevalence estimates of Antenatal Depression using a validated diagnostic/ screening tool identified, screened and appraised using a two-stage process. A meta-analysis was conducted using the proportion (%) of pregnant women identified as having Antenatal Depression as the primary outcome. Results Thirty-three studies involving 13,087 pregnant women were included in the meta-analysis. Overall pooled prevalence was 24·57% (95% CI: 19·34, 30·69). Prevalence rates for India (17·74%, 95% CI: 11·19, 26·96) and Sri Lanka (15·87%, 95% CI: 14·04, 17·88) were lower compared to the overall prevalence whereas the rates for Pakistan (32·2%, 95% CI: 23·11, 42·87) and Nepal (50%, 95% CI: 35·64,64·36) were higher. Conclusions While robust prevalence studies are sparse in most South Asian countries, one in four pregnant women is likely to experience Antenatal Depression in the region. The issue needs to be recognised in health policy and practice for resource allocation and capacity building at regional and national levels for prevention, diagnosis and treatment. Key messages One in four pregnant women is likely to experience Antenatal Depression in South Asia region. Targeted efforts are needed at national and regional levels for prevention, diagnosis and treatment.
-
Prevalence of Antenatal Depression in South Asia: a systematic review and meta-analysis
Journal of epidemiology and community health, 2019Co-Authors: Rahini Mahendran, Shuby Puthussery, M AmalanAbstract:Objective To estimate the prevalence of Antenatal Depression in South Asia and to examine variations by country and study characteristics to inform policy, practice and future research. Methods We conducted a comprehensive search of 13 databases including international databases and databases covering scientific literature from South Asian countries in addition to Google Scholar and grey sources from 1 January 2007 to 31 May 2018. Studies reporting prevalence estimates of Antenatal Depression using a validated diagnostic/screening tool were identified, screened, selected and appraised. Primary outcome was proportion (%) of pregnant women identified as having Antenatal Depression. Results Thirty-three studies involving 13 087 pregnant women were included in the meta-analysis. Twelve studies were rated as high quality and 21 studies were of moderate quality. Overall pooled prevalence of Antenatal Depression was 24.3 % (95% Confidence Interval (CI) 19.03 to 30.47). Studies showed a high degree of heterogeneity (I 2 =97.66%) and evidence of publication bias (p=0.668). Prevalence rates for India (17.74%, 95% CI 11.19 to 26.96) and Sri Lanka (12.95%, 95% CI 8.29 to 19.68) were lower compared with the overall prevalence, whereas prevalence rates for Pakistan (32.2%, 95% CI 23.11 to 42.87) and Nepal (50%, 95% CI 35.64 to 64.36) were higher. Conclusions While robust prevalence studies are sparse in most South Asian countries, available data suggest one in four pregnant women is likely to experience Antenatal Depression in the region. Findings highlight the need for recognition of the issue in health policy and practice and for resource allocation for capacity building at regional and national levels for prevention, diagnosis and treatment.
Alkistis Skalkidou - One of the best experts on this subject based on the ideXlab platform.
-
The effect of Antenatal Depression and antidepressant treatment on placental tissue: a protein-validated gene expression study
BMC Pregnancy and Childbirth, 2019Co-Authors: Åsa Edvinsson, Charlotte Hellgren, Theodora Kunovac Kallak, Susanne Lager, Romina Fornes, Helena Akerud, Alkistis Skalkidou, Olav Spigset, Elisabet Stener-victorin, Jocelien OlivierAbstract:BackgroundAntenatal Depression affects 10–20% of pregnant women. Around 2–4% of European pregnant women use antidepressant treatment, most commonly selective serotonin reuptake inhibitors (SSRIs). Poor pregnancy outcomes, such as preterm birth and low birth weight, have been described in women with Antenatal Depression and in pregnant women on SSRI treatment. However, the effects of Antenatal Depression and antidepressant treatment on the placenta are largely unknown. The aim of this work was to compare placental gene and protein expression in healthy women, women with untreated Antenatal Depression and women on antidepressant treatment during pregnancy.MethodsPlacental samples from 47 controls, 25 depressed and 45 SSRI-treated women were analysed by means of qPCR using custom-designed TaqMan low-density arrays (TLDAs) for 44 genes previously known to be involved in the pathophysiology of Depression, and expressed in the placenta. Moreover, placental protein expression was determined by means of immunohistochemistry in 37 healthy controls, 13 women with untreated Depression and 21 women on antidepressant treatment. Statistical comparisons between groups were performed by one-way ANOVA or the Kruskal–Wallis test.ResultsNominally significant findings were noted for HTR1A and NPY2R , where women with untreated Depression displayed higher gene expression than healthy controls ( p
-
The effect of Antenatal Depression and antidepressant treatment on placental tissue: a protein-validated gene expression study.
BMC pregnancy and childbirth, 2019Co-Authors: Åsa Edvinsson, Charlotte Hellgren, Susanne Lager, Romina Fornes, Helena Akerud, Alkistis Skalkidou, Olav Spigset, Elisabet Stener-victorin, Theodora Kunovac Kallak, Jocelien D. A. OlivierAbstract:Antenatal Depression affects 10–20% of pregnant women. Around 2–4% of European pregnant women use antidepressant treatment, most commonly selective serotonin reuptake inhibitors (SSRIs). Poor pregnancy outcomes, such as preterm birth and low birth weight, have been described in women with Antenatal Depression and in pregnant women on SSRI treatment. However, the effects of Antenatal Depression and antidepressant treatment on the placenta are largely unknown. The aim of this work was to compare placental gene and protein expression in healthy women, women with untreated Antenatal Depression and women on antidepressant treatment during pregnancy. Placental samples from 47 controls, 25 depressed and 45 SSRI-treated women were analysed by means of qPCR using custom-designed TaqMan low-density arrays (TLDAs) for 44 genes previously known to be involved in the pathophysiology of Depression, and expressed in the placenta. Moreover, placental protein expression was determined by means of immunohistochemistry in 37 healthy controls, 13 women with untreated Depression and 21 women on antidepressant treatment. Statistical comparisons between groups were performed by one-way ANOVA or the Kruskal–Wallis test. Nominally significant findings were noted for HTR1A and NPY2R, where women with untreated Depression displayed higher gene expression than healthy controls (p
-
The effects of Antenatal Depression and antidepressant treatment on placental gene expression
Frontiers in cellular neuroscience, 2015Co-Authors: Jocelien D. A. Olivier, Helena Akerud, Alkistis Skalkidou, Helena Kaihola, Inger Sundström-poromaaAbstract:The effects of Antenatal Depression and antidepressant treatment during pregnancy on both mother and child are vigorously studied, but the underlying biology for these effects is largely unknown. The placenta plays a crucial role in the growth and development of the fetus. We performed a gene expression study on the fetal side of the placenta to investigate gene expression patterns in mothers with Antenatal Depression and in mothers using antidepressant treatment during pregnancy. Placental samples from mothers with normal pregnancies, from mothers with Antenatal Depression, and from mothers using antidepressants were collected. We performed a pilot microarray study to investigate alterations in the gene expression and selected several genes from the microarray for biological validation with qPCR in a larger sample. In mothers with Antenatal Depression 108 genes were differentially expressed, whereas 109 genes were differentially expressed in those using antidepressants. Validation of the microarray revealed more robust gene expression differences in the seven genes picked for confirmation in antidepressant-treated women than in depressed women. Among the genes that were validated ROCK2 and C12orf39 were differentially expressed in both depressed and antidepressant-treated women, whereas ROCK1, GCC2, KTN1, and DNM1L were only differentially expressed in the antidepressant-treated women. In conclusion, Antenatal Depression and antidepressant exposure during pregnancy are associated with altered gene expression in the placenta. Findings on those genes picked for validation were more robust among antidepressant-treated women than in depressed women, possibly due to the fact that Depression is a multifactorial condition with varying degrees of endocrine disruption. It remains to be established whether the alterations found in the gene expression of the placenta are found in the fetus as well.
Helena Akerud - One of the best experts on this subject based on the ideXlab platform.
-
The effect of Antenatal Depression and antidepressant treatment on placental tissue: a protein-validated gene expression study
BMC Pregnancy and Childbirth, 2019Co-Authors: Åsa Edvinsson, Charlotte Hellgren, Theodora Kunovac Kallak, Susanne Lager, Romina Fornes, Helena Akerud, Alkistis Skalkidou, Olav Spigset, Elisabet Stener-victorin, Jocelien OlivierAbstract:BackgroundAntenatal Depression affects 10–20% of pregnant women. Around 2–4% of European pregnant women use antidepressant treatment, most commonly selective serotonin reuptake inhibitors (SSRIs). Poor pregnancy outcomes, such as preterm birth and low birth weight, have been described in women with Antenatal Depression and in pregnant women on SSRI treatment. However, the effects of Antenatal Depression and antidepressant treatment on the placenta are largely unknown. The aim of this work was to compare placental gene and protein expression in healthy women, women with untreated Antenatal Depression and women on antidepressant treatment during pregnancy.MethodsPlacental samples from 47 controls, 25 depressed and 45 SSRI-treated women were analysed by means of qPCR using custom-designed TaqMan low-density arrays (TLDAs) for 44 genes previously known to be involved in the pathophysiology of Depression, and expressed in the placenta. Moreover, placental protein expression was determined by means of immunohistochemistry in 37 healthy controls, 13 women with untreated Depression and 21 women on antidepressant treatment. Statistical comparisons between groups were performed by one-way ANOVA or the Kruskal–Wallis test.ResultsNominally significant findings were noted for HTR1A and NPY2R , where women with untreated Depression displayed higher gene expression than healthy controls ( p
-
The effect of Antenatal Depression and antidepressant treatment on placental tissue: a protein-validated gene expression study.
BMC pregnancy and childbirth, 2019Co-Authors: Åsa Edvinsson, Charlotte Hellgren, Susanne Lager, Romina Fornes, Helena Akerud, Alkistis Skalkidou, Olav Spigset, Elisabet Stener-victorin, Theodora Kunovac Kallak, Jocelien D. A. OlivierAbstract:Antenatal Depression affects 10–20% of pregnant women. Around 2–4% of European pregnant women use antidepressant treatment, most commonly selective serotonin reuptake inhibitors (SSRIs). Poor pregnancy outcomes, such as preterm birth and low birth weight, have been described in women with Antenatal Depression and in pregnant women on SSRI treatment. However, the effects of Antenatal Depression and antidepressant treatment on the placenta are largely unknown. The aim of this work was to compare placental gene and protein expression in healthy women, women with untreated Antenatal Depression and women on antidepressant treatment during pregnancy. Placental samples from 47 controls, 25 depressed and 45 SSRI-treated women were analysed by means of qPCR using custom-designed TaqMan low-density arrays (TLDAs) for 44 genes previously known to be involved in the pathophysiology of Depression, and expressed in the placenta. Moreover, placental protein expression was determined by means of immunohistochemistry in 37 healthy controls, 13 women with untreated Depression and 21 women on antidepressant treatment. Statistical comparisons between groups were performed by one-way ANOVA or the Kruskal–Wallis test. Nominally significant findings were noted for HTR1A and NPY2R, where women with untreated Depression displayed higher gene expression than healthy controls (p
-
The effects of Antenatal Depression and antidepressant treatment on placental gene expression
Frontiers in cellular neuroscience, 2015Co-Authors: Jocelien D. A. Olivier, Helena Akerud, Alkistis Skalkidou, Helena Kaihola, Inger Sundström-poromaaAbstract:The effects of Antenatal Depression and antidepressant treatment during pregnancy on both mother and child are vigorously studied, but the underlying biology for these effects is largely unknown. The placenta plays a crucial role in the growth and development of the fetus. We performed a gene expression study on the fetal side of the placenta to investigate gene expression patterns in mothers with Antenatal Depression and in mothers using antidepressant treatment during pregnancy. Placental samples from mothers with normal pregnancies, from mothers with Antenatal Depression, and from mothers using antidepressants were collected. We performed a pilot microarray study to investigate alterations in the gene expression and selected several genes from the microarray for biological validation with qPCR in a larger sample. In mothers with Antenatal Depression 108 genes were differentially expressed, whereas 109 genes were differentially expressed in those using antidepressants. Validation of the microarray revealed more robust gene expression differences in the seven genes picked for confirmation in antidepressant-treated women than in depressed women. Among the genes that were validated ROCK2 and C12orf39 were differentially expressed in both depressed and antidepressant-treated women, whereas ROCK1, GCC2, KTN1, and DNM1L were only differentially expressed in the antidepressant-treated women. In conclusion, Antenatal Depression and antidepressant exposure during pregnancy are associated with altered gene expression in the placenta. Findings on those genes picked for validation were more robust among antidepressant-treated women than in depressed women, possibly due to the fact that Depression is a multifactorial condition with varying degrees of endocrine disruption. It remains to be established whether the alterations found in the gene expression of the placenta are found in the fetus as well.
Åsa Edvinsson - One of the best experts on this subject based on the ideXlab platform.
-
The effect of Antenatal Depression and antidepressant treatment on placental tissue: a protein-validated gene expression study
BMC Pregnancy and Childbirth, 2019Co-Authors: Åsa Edvinsson, Charlotte Hellgren, Theodora Kunovac Kallak, Susanne Lager, Romina Fornes, Helena Akerud, Alkistis Skalkidou, Olav Spigset, Elisabet Stener-victorin, Jocelien OlivierAbstract:BackgroundAntenatal Depression affects 10–20% of pregnant women. Around 2–4% of European pregnant women use antidepressant treatment, most commonly selective serotonin reuptake inhibitors (SSRIs). Poor pregnancy outcomes, such as preterm birth and low birth weight, have been described in women with Antenatal Depression and in pregnant women on SSRI treatment. However, the effects of Antenatal Depression and antidepressant treatment on the placenta are largely unknown. The aim of this work was to compare placental gene and protein expression in healthy women, women with untreated Antenatal Depression and women on antidepressant treatment during pregnancy.MethodsPlacental samples from 47 controls, 25 depressed and 45 SSRI-treated women were analysed by means of qPCR using custom-designed TaqMan low-density arrays (TLDAs) for 44 genes previously known to be involved in the pathophysiology of Depression, and expressed in the placenta. Moreover, placental protein expression was determined by means of immunohistochemistry in 37 healthy controls, 13 women with untreated Depression and 21 women on antidepressant treatment. Statistical comparisons between groups were performed by one-way ANOVA or the Kruskal–Wallis test.ResultsNominally significant findings were noted for HTR1A and NPY2R , where women with untreated Depression displayed higher gene expression than healthy controls ( p
-
The effect of Antenatal Depression and antidepressant treatment on placental tissue: a protein-validated gene expression study.
BMC pregnancy and childbirth, 2019Co-Authors: Åsa Edvinsson, Charlotte Hellgren, Susanne Lager, Romina Fornes, Helena Akerud, Alkistis Skalkidou, Olav Spigset, Elisabet Stener-victorin, Theodora Kunovac Kallak, Jocelien D. A. OlivierAbstract:Antenatal Depression affects 10–20% of pregnant women. Around 2–4% of European pregnant women use antidepressant treatment, most commonly selective serotonin reuptake inhibitors (SSRIs). Poor pregnancy outcomes, such as preterm birth and low birth weight, have been described in women with Antenatal Depression and in pregnant women on SSRI treatment. However, the effects of Antenatal Depression and antidepressant treatment on the placenta are largely unknown. The aim of this work was to compare placental gene and protein expression in healthy women, women with untreated Antenatal Depression and women on antidepressant treatment during pregnancy. Placental samples from 47 controls, 25 depressed and 45 SSRI-treated women were analysed by means of qPCR using custom-designed TaqMan low-density arrays (TLDAs) for 44 genes previously known to be involved in the pathophysiology of Depression, and expressed in the placenta. Moreover, placental protein expression was determined by means of immunohistochemistry in 37 healthy controls, 13 women with untreated Depression and 21 women on antidepressant treatment. Statistical comparisons between groups were performed by one-way ANOVA or the Kruskal–Wallis test. Nominally significant findings were noted for HTR1A and NPY2R, where women with untreated Depression displayed higher gene expression than healthy controls (p